Endothelin-2 is upregulated in basal cell carcinoma under control of Hedgehog signaling pathway

2010 ◽  
Vol 391 (1) ◽  
pp. 486-491 ◽  
Author(s):  
Keiji Tanese ◽  
Mariko Fukuma ◽  
Akira Ishiko ◽  
Michiie Sakamoto
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Signaling Pathway ◽  
Basal Cell ◽  
Hedgehog Signaling ◽  
Hedgehog Signaling Pathway

scholarly journals Vismodegib: The Proof of Concept in Basal Cell Carcinoma

2014 ◽  
Vol 8 ◽  
pp. CMO.S14569 ◽  
Author(s):  
Narjiss Berrada ◽  
Siham Lkhoyali ◽  
Hind Mrabti ◽  
Hassan Errihani
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Signaling Pathway ◽  
Basal Cell ◽  
Hedgehog Signaling ◽  
Treatment Options ◽  
Locally Advanced ◽  
Scientific Data ◽  
Hedgehog Signaling Pathway ◽  
Proof Of Concept

Although basal cell carcinoma (BCC) is the most common cancer worldwide, its metastatic dissemination is exceptional. Before 2012, we had a few treatment options available for metastatic or locally advanced cases. Management of these patients was complicated due to the lack of scientific data, the deterioration of a patient's general status, the patient's advanced age, and the presence of multiple comorbidities. The hedgehog signaling pathway is dysregulated in BCC. The exploration of this signaling pathway yielded to a major milestone in the treatment of advanced BCC. Vismodegib (GDC-0449), an oral small-molecule agent that targets the Hedgehog signaling pathway, demonstrates high levels of activity in clinical trials. It was approved in January 2012 for the treatment of locally advanced or metastatic BCC. Vismodegib confirms, once again, the interest in exploring the signal transduction pathways in cancers.

Sign in / Sign up

Export Citation Format

Share Document